TECH · Bio-Techne Corporation
$71.002026-07-21Sector: Healthcare; Industry: Biotechnology; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$12
-82.6% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($13 · $12) Analysts Range ($50 · $79) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q3 | $1.1B | — | 30.1% | 12.6% | $299MM | −$146MM | $153MM | 9.9% | — | 11.8% | $2.5B | $1.82 | — |
| 2025.Q2 | $1.2B | 2.0% | 20.4% | 14.9% | $202MM | $186MM | $388MM | 11.4% | — | 8.0% | $2.5B | $1.07 | — |
| 2025.Q3 | $1.2B | 0.0% | 20.4% | 19.2% | $191MM | $179MM | $370MM | 10.6% | — | 7.6% | $2.5B | $1.07 | — |
| 2026.Q2 | $1.2B | 5.2% | 9.6% | 29.0% | $83MM | $69MM | $152MM | 11.0% | — | 3.4% | $2.4B | $0.47 | — |
| 2026.Q3 | $1.2B | -0.7% | 14.6% | 25.5% | $131MM | $76MM | $207MM | 10.3% | — | 5.5% | $2.4B | $0.70 | 63.2 |
| italics below = DCF projection · 10yr Rev CAGR: 5.1% |
| 2027.Q3 | $1.2B | +3.0% | 16.7% | 25.0% | $156MM | −$74MM | $82MM | 10.0% | $74MM | 6.5% | $2.5B | $0.76 | 93.4 |
| 2028.Q3 | $1.4B | +8.3% | 16.9% | 24.4% | $173MM | −$214MM | −$42MM | 9.9% | −$35MM | 6.7% | $2.7B | $0.86 | 82.6 |
| 2029.Q3 | $1.5B | +9.5% | 17.2% | 23.9% | $193MM | −$273MM | −$79MM | 9.7% | −$60MM | 6.9% | $2.9B | $1.00 | 71.0 |
| 2030.Q3 | $1.5B | +4.6% | 17.4% | 23.3% | $207MM | −$150MM | $57MM | 9.6% | $39MM | 6.8% | $3.1B | $1.09 | 65.1 |
| 2031.Q3 | $1.6B | +4.5% | 17.9% | 22.8% | $224MM | −$158MM | $65MM | 9.4% | $41MM | 7.0% | $3.3B | $1.25 | 56.8 |
|
| Term. Yr+ | $2.1B | 4.1% | 17.9% | 20.0% | $298MM | −$142MM | $156MM | 8.6% | $1.4B | 8.6% | — | — | — |
Active scenario IV: $12 (-82.6% vs market)